IgA Nephropathy Improved by a New Modality: MAM14 Immunotherapy: A Case Report in Kuwait

  • Saleh A. ALharbi
  • Ali S. Alharbi
Keywords: PBL, MAM14, Immunotherapy, FK 506, IgA nephropathy.


A 45 Year-old- Kuwaiti female with a case of IgA nephropathy (IgA N) was studied from 2002 to 2014 at Mubarak Hospital. The chief complaint was hematuria. In the first year she was given a conventional corticosteroid regimen. Her parameters at this stage are used as controls for the remainder of the study. She was treated with FK506 immunosuppressant capsules in the second year and vaccinated with allogeneic peripheral blood lymphocytes (PBL) in the third year. This study includes the following parameters: serum creatinine, serum albumin, IgA level, and 24-hour urine protein. In the first year the patient was only on corticosteroid, in the second year only FK506, and in the third year was treated only with PBL vaccination. A booster dose of vaccine was administered after approximately 5 years. The patient’s significant improvements after PBL vaccination have persisted for 9 years. The mechanism postulated for this kind of immunotherapy is induction of novel therapeutic antigens, including heat shock protein (HSP), that interact with autoreactive T or B cells in the recipient. The result is T regulatory cells (T-reg) claimed to be responsible for shifting T-cell detrimental function to regulatory function, hence preventing the pathological production and deposition of IgA in the kidney. Data accumulated from our lab, but not yet published, demonstrates that MAM14 immunotherapy ameliorates symptoms and signs of certain autoimmune disorders.


[1] R.J. Wyatt and B.A. Julian. “IgA nephropathy.” New England Journal of Medicine, vol. 368, pp. 2402-2414, Jun. 2013.
[2] KDIGO. (2012, Jun.). “KDIGO clinical practice guideline for glomerulonephritis.” Kidney International (Supplement), [On-line]. Available: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-GN-Guideline.pdf [December 23, 2013].
[3] G. D'Amico. “Influence of clinical and histological features on actuarial renal survival in adult patients with idiopathic IgA nephropathy, membranous nephropathy, and membranoproliferative glomerulonephritis: Survey of the recent literature.” American Journal of Kidney Diseases, vol. 20, no. 4, pp. 315-323, Nov. 1992.
[4] E. Alamartine, J.C. Sabatier, C. Guerin, J. Berliet, and F. Berthoux. “Prognostic factors in mesangial IgA glomerulonephritis: An extensive study with univariate and multivariate analyses.” American Journal of Kidney Diseases, vol. 18, no. 1, pp. 12-19, Jul. 1991.
[5] J.V. Donadio and J.P. Grande. “IgA nephropathy.” New England Journal of Medicine, vol. 347, no. 10, pp. 738-748, Sep. 2002.
[6] L.S. Li and Z.H. Liu. “Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies.” Kidney International, vol. 66, no. 3, pp. 920-923, Sep. 2004.
[7] C.C. Geddes, V. Rauta, C. Gronhagen-Riska, et al. “A tricontinental view of IgA nephropathy,” [On-line]. Nephrolology Dialysis Transplantation, vol. 18, no. 8, pp. 1541-1548, Aug. 2003.
[8] T.E. Hunley, B.A. Julian, J.A. Phillips, et al. “Angiotensin converting enzyme gene polymorphism: Potential silencer motif and impact on progression in IgA nephropathy. Kidney International, vol. 49, no. 2, pp. 571-577, Feb. 1996.
[9] M.F. McCarty and S.A. Alharbi. “Vaccination with heat shocked mononuclear cells as a strategy for treating neurodegenerative disorders driven by microglial inflammation.” Medical Hypotheses, vol. 81, no. 5, pp. 773-776, Nov. 2013.
[10] S.A. Alharbi and A.S. Alharbi. “MAM14 immunotherapy for certain autoimmune disorders.” 2015. In preparation.